(S1 (S (NP (JJ Human) (NN immunodeficiency) (NN virus-1) (NN Tat)) (VP (VBZ activates) (NP (NN NF-kappaB)) (PP (IN via) (NP (NP (JJ physical) (NN interaction)) (PP (IN with) (NP (NP (NN IkappaB-alpha)) (CC and) (NP (NN p65)))))))))
(S1 (S (S (NP (JJ Nuclear) (NN factor) (-LRB- -LRB-) (NN NF) (-RRB- -RRB-) (NN -kappaB)) (VP (VP (VBZ is) (NP (NP (DT a) (JJ master) (NN regulator)) (PP (IN of) (NP (JJ pro-inflammatory) (NNS genes))))) (CC and) (VP (VBZ is) (VP (VBN upregulated) (PP (IN in) (NP (NP (NP (JJ human) (NN immunodeficiency) (NN virus) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN HIV-1)) (-RRB- -RRB-))) (NN infection))))))) (. .)))
(S1 (S (S (NP (NP (NNS Mechanisms)) (VP (VBG underlying) (NP (NP (DT the) (NN NF-kappaB) (NN deregulation)) (PP (IN by) (NP (NN HIV-1)))))) (VP (VBP are) (ADJP (JJ relevant) (PP (IN for) (NP (NP (JJ immune) (NN dysfunction)) (PP (IN in) (NP (NN AIDS)))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP report) (SBAR (IN that) (S (PP (IN in) (NP (NP (JJ single) (NN round) (NN HIV-1) (NN infection)) (, ,) (CC or) (NP (JJ single-pulse) (NN PMA) (NN stimulation)))) (, ,) (NP (DT the) (NN HIV-1) (NN Tat) (NN transactivator)) (VP (VBD activated) (NP (NN NF-kappaB)) (PP (PP (IN by) (S (VP (VBG hijacking) (NP (DT the) (NN inhibitor) (NN IkappaB-alpha))))) (CC and) (PP (IN by) (S (VP (VBG preventing) (NP (NP (DT the) (NN repressor) (NN binding)) (PP (TO to) (NP (DT the) (NN NF-kappaB) (NN complex))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NN Tat)) (VP (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN p65) (NN subunit)) (PP (IN of) (NP (NN NF-kappaB)))))) (CC and) (VP (VBD increased) (NP (NP (DT the) (NN p65) (NN DNA-binding) (NN affinity)) (CC and) (NP (JJ transcriptional) (NN activity)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (ADJP (ADJP (JJ arginine-)) (CC and) (ADJP (JJ cysteine-rich))) (NNS domains)) (PP (IN of) (NP (NN Tat)))) (VP (VBD were) (VP (VBN required) (PP (PP (IN for) (NP (NP (NP (NN IkappaB-alpha)) (CC and) (NP (NN p65)) (NP (NN association))) (, ,) (ADVP (RB respectively)))) (, ,) (CC and) (PP (IN for) (S (VP (VBG sustaining) (NP (DT the) (NN NF-kappaB) (NN activity))))))))) (. .)))
(S1 (S (S (PP (IN Among) (NP (NP (DT an) (NN array)) (PP (IN of) (NP (JJ NF-kappaB-responsive) (NNS genes))))) (, ,) (NP (NN Tat)) (VP (ADVP (RB mostly)) (VP (VBD activated) (NP (DT the) (NN MIP-1alpha) (NN expression)) (PP (IN in) (NP (DT a) (JJ p65-dependent) (NN manner)))) (, ,) (CC and) (VP (VBD bound) (PP (TO to) (NP (DT the) (NN MIP-1alpha) (NN NF-kappaB) (NN enhancer))) (S (ADVP (RB thus)) (VP (VBG promoting) (NP (NP (DT the) (NN recruitment)) (PP (IN of) (NP (NN p65))) (PP (IN with) (NP (NP (NN displacement)) (PP (IN of) (NP (NN IkappaB-alpha))))))))))) (: ;) (S (NP (JJ similar) (NNS findings)) (VP (VBD were) (VP (VBN obtained) (PP (IN for) (NP (DT the) (JJ NF-kappaB-responsive) (NNS genes) (NP (NP (NN CSF3)) (, ,) (NP (NN LTA)) (, ,) (NP (NN NFKBIA)) (CC and) (NP (NN TLR2)))))))) (. .)))
(S1 (S (S (NP (PRP$ Our) (NNS results)) (VP (VP (VBP support) (NP (NP (DT a) (JJ novel) (NN mechanism)) (PP (IN of) (NP (NN NF-kappaB) (NN activation)))) (PP (IN via) (NP (NP (JJ physical) (NN interaction)) (PP (IN of) (NP (NN Tat))) (PP (IN with) (NP (NP (NN IkappaB-alpha)) (CC and) (NP (NN p65))))))) (, ,) (CC and) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (JJ further) (NNS insights)) (PP (IN into) (NP (NP (DT the) (NN deregulation)) (PP (IN of) (NP (DT the) (JJ inflammatory) (NN response))) (PP (IN by) (NP (NN HIV-1))))))))))) (. .)))
